ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO051

Post-Transplant Survival Among Patients with Pretransplant Treatment for Prostate Cancer

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical

Authors

  • Sarabu, Nagaraju, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
  • Schiltz, Nicholas K., Case Western Reserve University, Cleveland, Ohio, United States
Background

Optimal pre-kidney transplant treatment and waiting time for transplant among patients with prostate cancer is unclear.

Methods

We studied male patients, 40 years or older, with ESRD who had Medicare claims for prostate cancer and two main types of treatment (radiation and prostatectomy) utilizing USRDS (United States Renal Data System). We stratified patients into three categories based on waiting time to transplant from the time the prostate cancer was treated (0-2, 2-5, >5 years). We used Kaplan-Meier method to compare post-transplant survival among the strata. We used Cox proportional hazards model to assess relative risks of death between the groups.

Results

There were a total of 920 patients who had kidney transplants with prior history of treatment for prostate cancer. Figure 1a shows KM curves, stratified by waiting time (p-values = <0.01). Compared to 0-2 years of waiting time, 2-5 years had 13% higher likelihood of death (HR: 1.13, 95% CI:0.88-1.44) and >5 years had 73% higher likelihood of death (HR: 1.73, 95% CI:1.30-2.3). Prostatectomy was associated with a better post-transplant survival than radiation (Figure 1b).

Conclusion

Prostatectomy and kidney transplant without significant delay may be optimal choices for patients with prostate cancer and eligible for kidney transplant.

Kaplan Meier survival curves for patients, stratified by waiting time (1a) and type of treatment (1b)